EverLife Capital
Stop Reading About Longevity.
Start Knowing What To Do With It.
Most people following this space end up with a lot of interesting information and no clear framework for applying it. They know the words – senolytics, mTOR, epigenetic reprogramming – but they cannot evaluate a company’s science with any real discipline. They track their steps but not their ApoB. They find longevity biotech compelling but still feel like they are on the outside of the analysis looking in.
That gap is exactly what this bundle is built to close.
Here is how I got here. I started writing about longevity biotech and quickly realized the articles were only useful if readers understood the system behind them. So I kept writing, kept refining the framework, kept testing it against new companies and new data. About two years of writing, rebuilding, and refining is what produced these four tools. The articles are the output. This bundle is the engine behind them.
Why Readers Get This After The First Few Articles
I hear the same question in different forms: “How do I actually apply this framework to evaluate companies myself, rather than just following your read on each one?” The bundle is the direct answer to that.
- 1. Each article covers one mechanism. The bundle shows how all the mechanisms connect into one coherent research framework. Once you have that full picture, you stop looking at companies in isolation and start seeing how the pieces fit together.
- 2. The Microcap Target List shows the companies that have passed the same L-45 filter I describe in every article. You get the full scored output with milestone dates, not just a description of the methodology.
- 3. The 45+ Baseline Matrix turns “biological ROI” from a concept into something you can actually measure. These are the specific tests worth running and the reference ranges that matter for your age group. I use this protocol personally.
- 4. Once you have read the 25-Gate Evaluation System, every future article becomes a faster, more useful read. You will understand which criteria each company is passing or struggling with before I even get to that section. That is the shift from consuming research to being able to use it.
I am 52. I have a BS in Computer Engineering from UCSD and spent 25 years building CuraDebt into one of the most recognized names in debt relief – I sold part of the business in early 2025 and turned my full attention to this. I track my own biomarkers with an Ultrahuman Ring and get bloodwork done on a schedule most people would call excessive. I have been actively investing in and monitoring longevity companies for 2+ years, and I want to be functional at 100 – I am planning to have kids in the next few years who I want to be genuinely present for well into their adult lives.
That is why both sides of this matter to me. The financial analysis and the biological health tracking are not separate things. They are the same thesis applied to two different domains. The companies most interesting to research are the ones building science that could make a real difference for a 45+ investor who still has 50 or more good years ahead. That is the filter behind everything in this bundle.
The articles will keep coming. The bundle is what makes every one of them actionable rather than just interesting.
Get Instant Access – $149One-time payment. Instant delivery. No subscription required.